Optimizing Commercial Development

RCP is a global, value creation focused firm dedicated to optimizing commercial development of rare and ultra-rare disease assets for clinical-stage biotech companies.

RCP was born out of a desire to build a true legacy of innovation to help patients living with rare disease. We have repeatedly witnessed rare disease companies incorporate commercial thinking too late and too slowly, fail to execute on strategy and incorrectly interpret and leverage insights resulting in suboptimal launches, missed opportunities, decreased returns for investors and delays in access and availability of treatment for patients.

This observable inefficiency was the catalyst which served to inspire the coalescing of a team of experts not found anywhere else in the industry.

Collectively, RCP brings more than 125 years in rare disease and 30 years in gene therapy of combined global commercialization experience having created new markets and launched 16 products across 17 therapeutic areas.

Our Private Markets practice is uniquely positioned to service our Private Equity and Venture Capital owned clients. Optimized commercial readiness and launch is a path to quickly unlock your organizations potential, drive Time to Value and ultimately a positive impact to EBITDA.

RCP has executed global launch planning in more than 5 major and emerging markets covering the U.S., Canada, European Union, South America, Australasia and Japan in over 12 countries.